Literature DB >> 36147789

Impact of achieving euthyroidism on pulmonary artery systolic pressures in hyperthyroidism-associated pulmonary hypertension - a systematic review.

Shireen R Chacko1, Pradhum Ram2, Tamaryn Fox1, Naveen Sooknanan1, Kevin Bryan Lo1, Ritesh G Menezes3, Savita Lasrado4, Glenn Eiger1,5, Anjali Vaidya6.   

Abstract

In this systematic review, we seek to clarify the impact of treatment of hyperthyroidism on pulmonary hypertension in patients with both these conditions. We included 39 of 709 articles retrieved, that studied patients with hyperthyroidism and pulmonary hypertension (PH). From these, those with a documented pre-treatment Pulmonary Artery Systolic Pressure (PASP) > 35 mmHg and complete follow up were analyzed, yielding 3 case series and 22 case reports with a total of 81 cases. A significant improvement in PASP was noted with achieving euthyroidism in the 3 case series. The case reports showed a significant reduction in mean PASP from 60.5 ± 13.2 mmHg to 37.5 ± 10.1 mmHg (p < 0.001) in patients with Grave's disease with achieving euthyroidism. No deaths were reported during the follow up period. Achievement of a euthyroid state in patients with hyperthyroidism is associated with statistically significant reductions in PASP. AJCD
Copyright © 2022.

Entities:  

Keywords:  Hyperthyroidism; pulmonary hypertension

Year:  2022        PMID: 36147789      PMCID: PMC9490158     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  59 in total

1.  Reversible severe tricuspid regurgitation with right heart failure associated with thyrotoxicosis.

Authors:  Jae-Hyeong Park; Minho Shong; Jae-Hwan Lee; Si Wan Choi; Jin Ok Jeong; In-Whan Seong
Journal:  Thyroid       Date:  2006-08       Impact factor: 6.568

2.  Severe reversible right heart failure in a patient with hyperthyroidism.

Authors:  V Syriou; S C Plastiras; T Paterakis; I Moyssakis; P Vlachoyiannopoulos
Journal:  Int J Clin Pract       Date:  2008-02       Impact factor: 2.503

Review 3.  Right heart catheterisation: best practice and pitfalls in pulmonary hypertension.

Authors:  Stephan Rosenkranz; Ioana R Preston
Journal:  Eur Respir Rev       Date:  2015-12

4.  Pulmonary hypertension and isolated right heart failure complicating amiodarone induced hyperthyroidism.

Authors:  Sean-Man Wong; Hung-Fat Tse; Chung-Wah Siu
Journal:  Heart Lung Circ       Date:  2011-12-08       Impact factor: 2.975

5.  Prevalence of echocardiographic criteria for the diagnosis of pulmonary hypertension in patients with Graves' disease: before and after antithyroid treatment.

Authors:  J H Suk; K I Cho; S H Lee; H G Lee; S M Kim; T I Kim; M K Kim; Y K Shong
Journal:  J Endocrinol Invest       Date:  2011-03-07       Impact factor: 4.256

6.  Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface.

Authors:  Faith B Davis; Shaker A Mousa; Laura O'Connor; Seema Mohamed; Hung-Yun Lin; H James Cao; Paul J Davis
Journal:  Circ Res       Date:  2004-04-29       Impact factor: 17.367

Review 7.  Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature.

Authors:  Hector F Lozano; Charu N Sharma
Journal:  Cardiol Rev       Date:  2004 Nov-Dec       Impact factor: 2.644

8.  Shortness of Breath and Lower Limb Edema in a 54-Year-Old Woman, Is There Any Cure?

Authors:  Alexandra Frogoudaki; Andreas S Triantafyllis; Evangeline Vassilatou; Charalampos Tsamakis; Achilles Zacharoulis; John Lekakis
Journal:  Res Cardiovasc Med       Date:  2015-12-09

9.  Right ventricular dysfunction and pulmonary hypertension: a neglected presentation of thyrotoxicosis.

Authors:  Carolina Shalini Singarayar; Foo Siew Hui; Nicholas Cheong; Goay Swee En
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-05-16

10.  The Relation of Dependency and the Predictive Potential of Several Factors Possibly Involved in Determining Pulmonary Hypertension in Graves' Disease.

Authors:  Camelia C Scarneciu; Livia Sangeorzan; Mihaela Popescu; Vlad D Scarneciu; Ioan Scarneciu
Journal:  Pak J Med Sci       Date:  2018 May-Jun       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.